Xaira Therapeutics, an AI-driven biotech launched in April 2024 with over $1 billion in funding, has appointed Dr. Bo Wang as Senior Vice President and Head of Biomedical AI. The company is focused on building an end-to-end drug development platform that integrates large-scale data generation, multimodal foundation models, and generative design tools for protein therapeutics. Its approach combines AI-native frameworks for understanding disease biology, algorithms for de novo protein and antibody design, and predictive systems to optimize patient…
